Search for a trial

A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension

To evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension (PAH).

Effects of bosentan in a homogeneous population of SSc subjects with a predefined restriction of blood flow in the hands

The primary objectives are:- To demonstrate the relationship of blood flow in the hands and the extent of digital ulcera in patients with systemic scleroderma;- Evaluate the effect of bosentan on the blood flow in the hands from baseline to 12 weeks…

Effects of bosentan in a homogeneous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern

Primairy objective:- Evaluate the effect of bosentan on the blood flow in the hands from baseline to 12 weeks, measured by laser Doppler imaging, in SSc subjects with an early or active SSc pattern, measured with nailfold capillaroscopy (NFM), with…

Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 BUILD-3

To assess long-term safety and tolerability of bosentan in patients with IPF.